과제정보
The authors thank investigators from all participating study centers for their contribution to conduct of study. The authors also acknowledge Rajendra Prasad for expert review of this draft. Medical writing support was provided by Vatsal Vithlani and Rahul Lad (professional medical writers from Novartis) under author's guidance. The article was prepared in accordance with the third edition of Good Publication Practice guidelines.
참고문헌
- World Health Organization Fact Sheet. Chronic obstructive pulmonary disease (COPD) [Internet]. Geneva: World Health Organization; 2017 [cited 2019 Jan 8]. Available from: https://www.who.int/news-room/fact-sheets/detail/chronicobstructive-pulmonary-disease-(copd).
- Hwang YI, Park YB, Yoo KH. Recent trends in the prevalence of chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis 2017;80:226-9. https://doi.org/10.4046/trd.2017.80.3.226
- Park H, Jung SY, Lee K, Bae WK, Lee K, Han JS, et al. Prevalence of chronic obstructive lung disease in Korea using data from the fifth Korea national health and nutrition examination survey. Korean J Fam Med 2015;36:128-34. https://doi.org/10.4082/kjfm.2015.36.3.128
- Kim C, Kim Y, Yang DW, Rhee CK, Kim SK, Hwang YI, et al. Direct and indirect costs of chronic obstructive pulmonary disease in Korea. Tuberc Respir Dis 2019;82:27-34. https://doi.org/10.4046/trd.2018.0035
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD [Internet]. Fontana: Global Initiative for Chronic Obstructive Lung Disease; 2019 [cited 2019 Dec 8]. Available from: https://goldcopd.org/.
- Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010;23:257-67. https://doi.org/10.1016/j.pupt.2010.03.003
- COPD Monitoring, Market research data from Ipsos Mar (2014) [Internet]. Seoul: IPSOS Korea; 2014 [cited 2019 Dec 8]. Available from: http://www.ipsoskorea.com/Eng/healthcare.html.
- Park YB, Rhee CK, Yoon HK, Oh YM, Lim SY, Lee JH, et al. Revised (2018) COPD clinical practice guideline of the Korean Academy of Tuberculosis and Respiratory Disease: a summary. Tuberc Respir Dis 2018;81:261-73. https://doi.org/10.4046/trd.2018.0029
- D'Urzo AD, Kardos P, Wiseman R. Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD. Int J Chron Obstruct Pulmon Dis 2018;13: 1089-104. https://doi.org/10.2147/COPD.S160577
- Asai K, Hirata K, Hashimoto S, Fukuchi Y, Kitawaki T, Ikeda K, et al. Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: pooled analysis of SHINE and ARISE. Respir Investig 2016;54:428-35. https://doi.org/10.1016/j.resinv.2016.06.006
- Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013;42:1484-94. https://doi.org/10.1183/09031936.00200212
- Buhl R, Gessner C, Schuermann W, Foerster K, Sieder C, Hiltl S, et al. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study. Thorax 2015;70:311-9. https://doi.org/10.1136/thoraxjnl-2014-206345
- Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res 2017;18:140. https://doi.org/10.1186/s12931-017-0622-x
- Kaplan A, Chapman KR, Anees SM, Mayers I, Rochdi D, Djandji M, et al. Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/ fluticasone therapy in patients with symptomatic COPD: the POWER study. Int J Chron Obstruct Pulmon Dis 2019;14:249-60. https://doi.org/10.2147/COPD.S185485
- Rhee CK, Park HY, Park JW, Lee JH, Kim TH, Lee SW, et al. Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial. Trials 2017;18:80. https://doi.org/10.1186/s13063-017-1800-3
- Frith PA, Ashmawi S, Krishnamurthy S, Gurgun A, Hristoskova S, Pilipovic V, et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: the FLASH randomized controlled trial. Respirology 2018;23:1152-9. https://doi.org/10.1111/resp.13374
- Lim JU, Lee JH, Kim JS, Hwang YI, Kim TH, Lim SY, et al. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. Int J Chron Obstruct Pulmon Dis 2017;12:2465-75. https://doi.org/10.2147/COPD.S141295
- Wedzicha JA, Dahl R, Buhl R, Schubert-Tennigkeit A, Chen H, D'Andrea P, et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med 2014;108:1498-507. https://doi.org/10.1016/j.rmed.2014.07.011
피인용 문헌
- Time to Prescribe Dual instead of Mono vol.84, pp.3, 2021, https://doi.org/10.4046/trd.2021.0030